Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.
<h4>Background</h4>Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this r...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280582&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540073510305792 |
|---|---|
| author | Gillian Parker Sarah Hunter Samer Ghazi Robin Z Hayeems Francois Rousseau Fiona A Miller |
| author_facet | Gillian Parker Sarah Hunter Samer Ghazi Robin Z Hayeems Francois Rousseau Fiona A Miller |
| author_sort | Gillian Parker |
| collection | DOAJ |
| description | <h4>Background</h4>Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported.<h4>Methods</h4>We conducted a search of four databases, Medline, Embase, Scopus and Web of Science, from inception to June 2022. Empirical studies that reported a "decision impact" assessment of a genomic assay on treatment decisions or recommendations for cancer patients were included. We followed scoping review methodology and adapted the Fryback and Thornbury Model to collect and analyze data on clinical utility. The database searches identified 1803 unique articles for title/abstract screening; 269 articles moved to full-text review.<h4>Results</h4>87 studies met inclusion criteria. All studies were published in the last 12 years with the majority for breast cancer (72%); followed by other cancers (28%) (lung, prostate, colon). Studies reported on the impact of 19 different proprietary (18) and generic (1) assays. Across all four levels of clinical utility, outcomes were reported for 22 discrete measures, including the impact on provider/team decision-making (100%), provider confidence (31%); change in treatment received (46%); patient psychological impacts (17%); and costing or savings impacts (21%). Based on the data synthesis, we created a comprehensive table of outcomes reported for clinical utility.<h4>Conclusions</h4>This scoping review is a first step in understanding the evolution and uses of decision impact studies and their influence on the integration of emerging genomic technologies in cancer care. The results imply that DIS are positioned to provide evidence of clinical utility and impact clinical practice and reimbursement decision-making in cancer care. Systematic review registration: Open Science Framework osf.io/hm3jr. |
| format | Article |
| id | doaj-art-cd4cf6ed78ea498d8abd4d7fc4f771f2 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-cd4cf6ed78ea498d8abd4d7fc4f771f22025-02-05T05:32:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01183e028058210.1371/journal.pone.0280582Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review.Gillian ParkerSarah HunterSamer GhaziRobin Z HayeemsFrancois RousseauFiona A Miller<h4>Background</h4>Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported.<h4>Methods</h4>We conducted a search of four databases, Medline, Embase, Scopus and Web of Science, from inception to June 2022. Empirical studies that reported a "decision impact" assessment of a genomic assay on treatment decisions or recommendations for cancer patients were included. We followed scoping review methodology and adapted the Fryback and Thornbury Model to collect and analyze data on clinical utility. The database searches identified 1803 unique articles for title/abstract screening; 269 articles moved to full-text review.<h4>Results</h4>87 studies met inclusion criteria. All studies were published in the last 12 years with the majority for breast cancer (72%); followed by other cancers (28%) (lung, prostate, colon). Studies reported on the impact of 19 different proprietary (18) and generic (1) assays. Across all four levels of clinical utility, outcomes were reported for 22 discrete measures, including the impact on provider/team decision-making (100%), provider confidence (31%); change in treatment received (46%); patient psychological impacts (17%); and costing or savings impacts (21%). Based on the data synthesis, we created a comprehensive table of outcomes reported for clinical utility.<h4>Conclusions</h4>This scoping review is a first step in understanding the evolution and uses of decision impact studies and their influence on the integration of emerging genomic technologies in cancer care. The results imply that DIS are positioned to provide evidence of clinical utility and impact clinical practice and reimbursement decision-making in cancer care. Systematic review registration: Open Science Framework osf.io/hm3jr.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280582&type=printable |
| spellingShingle | Gillian Parker Sarah Hunter Samer Ghazi Robin Z Hayeems Francois Rousseau Fiona A Miller Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. PLoS ONE |
| title | Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. |
| title_full | Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. |
| title_fullStr | Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. |
| title_full_unstemmed | Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. |
| title_short | Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. |
| title_sort | decision impact studies evidence of clinical utility for genomic assays in cancer a scoping review |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0280582&type=printable |
| work_keys_str_mv | AT gillianparker decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview AT sarahhunter decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview AT samerghazi decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview AT robinzhayeems decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview AT francoisrousseau decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview AT fionaamiller decisionimpactstudiesevidenceofclinicalutilityforgenomicassaysincancerascopingreview |